Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)

Published:2010-07-14 Issue:7 Volume:40 Page:686-692
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:

Author:

Kudo Masatoshi,Kubo Shouji,Takayasu Kenichi,Sakamoto Michiie,Tanaka Masatoshi,Ikai Iwao,Furuse Junji,Nakamura Kenji,Makuuchi Masatoshi,

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2010.00674.x/fullpdf

Reference17 articles.

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

2. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma;Takayasu;Am J Roentgenol,2000

3. The criteria for the evaluation of direct treatment effects in hepatocellular carcinoma;The Liver Cancer Study Group of Japan;Acta Hepatol Jpn,1994

4. The criteria for the evaluation of direct treatment effects in hepatocellular carcinoma;The Liver Cancer Study Group of Japan;Acta Hepatol Jpn,2004

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The State of Systematic Therapies in Clinic for Hepatobiliary Cancers;Journal of Hepatocellular Carcinoma;2024-03

2. Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues;Hepatology International;2024-02-08

3. Report of the 23rd nationwide follow‐up survey of primary liver cancer in Japan (2014–2015);Hepatology Research;2023-09-05

4. Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates;Cancers;2023-08-23

5. 第23回全国原発性肝癌追跡調査報告（2014～2015）;Kanzo;2023-08-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3